Abstract Submission - GENERAL TERMS AND CONDITIONS

1) The submitting authors can modify the author information, category and core data of the abstract directly on the submission system until the deadline given. Please be aware that there will be no extension possible.

2) By submitting this abstract, I understand that my abstract, including names, is stored electronically and may be published on the EAACI website and EAACI content platforms. Failure to present your abstract will result in exclusion from online publishing on the EAACI website and EAACI content platform.

3) By submitting this abstract, I understand that my personal data will be stored and shared with EAACI, CYIM, the EAACI Committees, and abstract reviewers involved in the abstract selection for the Immunology Winter School 2024 event. Transfer of personal data to contractors as well as EAACI related scientific organisations may occur for production, promotion and dissemination of event content.

4) By submitting this abstract, I agree to transfer the copyright to EAACI. Consent will be asked upon submission for video recordings (webcast), live streaming of the presentation, or poster presentation.

5) Trade names are not allowed as well as copyright and trademark symbols. Non-proprietary (generic) names of drugs, written in lower case, are required the first time a drug is mentioned in the text. References, credits or the authors’ academic degrees or grant support are not to be included in the abstract. Standard abbreviations may be employed in the text. Place special or unusual abbreviations in parentheses after the full wording at the first time it appears in the body of the text. Company names and logos are not allowed in the title but can be named in the authors’ affiliation.

6) The abstracts will be assessed by an expert panel of reviewers. The reviewers have been selected by the Organising Committee to review abstracts in their category that best fits their expertise.

EAACI aims for excellent quality of science without compromising scientific integrity. The abstract reviewers are required to identify abstracts pertaining to commercial promotion of a proprietary product, data originating from the same study across several abstracts in order to notify the Organising Committee.

Please note that the final decisions regarding the allocation and the type of presentation of the submitted abstract will be made by the Organising Committee. No rescheduling or changes by the submitters will be possible once the abstract deadline is closed.

7) The presenting author receives all correspondence concerning the abstract and is responsible for informing all co-authors of the status of the abstract. The presenting author of an abstract must register for the meeting by the given deadline. If EAACI does not receive your registration and payment by the deadline, your abstract will be removed from the programme.

8) CONSENT FOR PUBLICATION OF INDIVIDUAL PATIENT DATA
Only applies to abstracts with identifiable patient information.

For the publication of an abstract that contains identifiable information about patients it is necessary that patients have given consent for the research to be published. For all abstracts that include identifiable patient details (e.g. gender, age, illness, location) or images, written informed consent for the publication of these must be obtained from the patient (or their parent or legal guardian).

By agreeing to these terms, I confirm that:
a. Written informed consent for publication of these clinical details and/or clinical images included in my abstract presentation was obtained from the patient/parent/guardian/relative of the patient (please include an explanatory statement in your abstract text).
b. The final decision on whether consent to publish is required or not lies with EAACI.

9) DUPLICATION OF PUBLICATION
Abstracts will only be considered for presentation if they are not published or submitted for presentation elsewhere. Applicants should submit novel and previously not published data.

Once the abstract has been accepted by EAACI it is automatically subject to the EAACI embargo guidelines.

10) DECLARATION OF CONFLICT OF INTEREST
EAACI is committed to ensuring the integrity of its scientific, educational, and research programmes. Abstract submission requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict. The submitter is responsible for obtaining disclosure information from all co-authors, to be entered in the author section of the submission page.

11) DISCLAIMER
The liability of EAACI is excluded to the extent permitted by law.

EAACI does not examine the Presentation and its content. Therefore, EAACI is not liable for its content, legality, and compliance with industry standards.

The author(s) agree(s) to indemnify and hold harmless EAACI, its governing bodies, officers, agents and employees against any claims, demands, suits, costs, damages or other liability (including reasonable attorneys’ fees) arising from the Uploading onto the EAACI Website or the Presentation at the Event except for any claims, demands, suits, costs, damages or other liability resulting from EAACI’s unlawful intent or gross negligence.

12) APPLICABLE LAW AND LEGAL VENUE
These Terms & Conditions and the legal relationship between EAACI and the author(s) are governed by Swiss law.

The legal venue for all legal disputes arising from and relating to these Terms & Conditions is agreed to be Zurich, Switzerland.

13) Severability
If any individual provisions of these Terms & Conditions should be entirely or partially void and/or ineffective, this shall not affect the validity and/or effectiveness of the remaining provisions or parts of such provisions. The invalid and/or ineffective provisions shall be replaced by ones that come closest to the spirit and purpose of the invalid and/or ineffective provisions in a legally valid form. The same applies to any gaps in these Terms & Conditions.